SCHEDULE: Sio Capital Discloses 2.69% Stake in Bright Minds Biosciences
Amendment to Beneficial Ownership Report
Sio Capital Management, LLC has filed an amended Schedule 13G, reporting a 2.69% beneficial ownership stake in Bright Minds Biosciences Inc. as of September 30, 2025.
Summary
- Sio Capital Management, LLC, an investment adviser, reported beneficial ownership of 190,764 Common Shares of Bright Minds Biosciences Inc.
- This ownership represents 2.69% of the issuer's Common Shares outstanding.
- The percentage is based on 7,088,639 Common Shares outstanding as of August 22, 2025, as disclosed by Bright Minds Biosciences Inc. in its Form F-3 on August 26, 2025.
- Sio Capital Management, LLC holds shared voting power and shared dispositive power over all 190,764 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a standard regulatory disclosure of beneficial ownership, indicating a neutral sentiment. It neither provides positive nor negative operational or financial news for the issuer.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Bright Minds Biosciences Inc. or Sio Capital Management, LLC regarding the issuer's future performance.
Management Comments
- Sio Capital Management, LLC certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing is a routine disclosure of an investment adviser's passive stake in a publicly traded company. It does not provide specific insights into broader industry trends or competitive landscape, but rather reflects an investment decision by Sio Capital Management, LLC in Bright Minds Biosciences Inc.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can be a factor in market perception.
- Management: Awareness of a notable institutional holder, though the filing explicitly states the stake is not for influencing control.
Key Dates
| Date | Description |
|---|---|
| 2025-08-22 | Date as of which 7,088,639 Common Shares of Bright Minds Biosciences Inc. were outstanding, as disclosed in the Issuer's Form F-3. |
| 2025-08-26 | Date of the Issuer's Form F-3 filing disclosing the number of outstanding shares. |
| 2025-09-30 | Date of the event which requires the filing of this statement, representing the reporting period end date for the beneficial ownership. |
| 2025-10-31 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Bright Minds Biosciences, Sio Capital Management, Schedule 13G, Beneficial Ownership, Common Shares, Investment Adviser, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.